MOMBA

Key Product Details

Product Description

MOMBA is a selective orthosteric agonist for human free fatty acid 2 (hFFA2) engineered receptors, designer receptors activated by designer drugs (DREADD), it shows no activity to wild-type hFFA2, hFFA3, and mouse FFA2. MOMBA inhibit forskolin-stimulated cAMP levels in cells expressing the hFFA2-DREADD receptor with improved potency and equivalent efficacy to Sorbic acid (Cat. No. 7119). In hFFA2-DREADD transgenic mice, MOMBA treatment significantly reduces gut transit and promotes concentration-dependent release of GLP-1 from colonic crypts. Orally bioavailable.

Product Specifications for MOMBA

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for MOMBA

The following data is based on the product molecular weight 166.17.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	6.02 mL	30.09 mL	60.18 mL
5 mM	1.20 mL	6.02 mL	12.04 mL
10 mM	0.60 mL	3.01 mL	6.02 mL
50 mM	0.12 mL	0.60 mL	1.20 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Miura Chemogenetics of cell surface receptors: beyond genetic and pharmacological approaches. RSC Chem.Biol. 2022 PMID: 35359495
• Milligan Chemogenetic approaches to explore the functions of free fatty acid receptor 2. Trends Pharmacol.Sci. 2021 PMID: 33495026
• Barki Chemogenetics defines a short-chain fatty acid receptor gut-brain axis. Elife 2022 PMID: 35229717

Product Documents for MOMBA